• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成人百日咳报告率及破伤风、白喉、无细胞百日咳疫苗/加强剂接种覆盖率:基层医疗中建立流行病学监测点的契机

Pertussis Notification Rate and Tdpa Vaccine/Booster Coverage in Adults: An Opportunity for an Epidemiological Observatory in Primary Care.

作者信息

Lapi Francesco, Marconi Ettore, Cricelli Iacopo, Rossi Alessandro, Mastronuzzi Tecla, Gabutti Giovanni, Cricelli Claudio

机构信息

Health Search, Italian College of General Practitioners and Primary Care, Via del Sansovino 179, 50142 Florence, Italy.

Genomedics SRL, 50141 Florence, Italy.

出版信息

Infect Dis Rep. 2024 Sep 2;16(5):870-879. doi: 10.3390/idr16050068.

DOI:10.3390/idr16050068
PMID:39311209
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11417937/
Abstract

: In recent years, Europe has experienced a significant increase in pertussis cases. One reason behind this rise is the decline in diphtheria-tetanus-pertussis (dTap) booster coverage among adults. Currently, Italy lacks a reliable monitoring system to track pertussis infections and vaccine coverage among adults. We therefore evaluated the reliability of a primary care framework to respond to this need. : Using an Italian primary care database for individuals aged 15 or above, we determined the pertussis infection notification rate and dTap vaccine/booster coverage for the timeframe of 2009-2022. : In the overall population, we obtained a lifetime occurrence rate of pertussis infections of 7.52 per 10,000 individuals. The annual incidence rates of pertussis infections ranged from 0.008 to 0.001 per 10,000 person-years between 2009 and 2022. A rising trend in dTap vaccine coverage rate (ranging from 8.72 to 16.54 vaccines per 10,000 individuals) was observed during the same period. Notably, those aged 65 or older, smokers, and/or individuals with immunodeficiencies were more likely to receive the dTap vaccine compared to the general population. : Given the organization of the Italian public health system, this primary care network might act as a reliable epidemiological monitoring system to keep track of pertussis infections and dTap vaccine coverage in adults. Pertussis cases were underreported, and there was a low uptake of vaccines and boosters. Therefore, it is crucial to closely monitor pertussis notifications and dTap administrations and develop intervention strategies at the national level to enhance vaccine-related prevention.

摘要

近年来,欧洲百日咳病例显著增加。这一增长背后的一个原因是成人白喉-破伤风-百日咳(dTap)加强疫苗接种覆盖率下降。目前,意大利缺乏一个可靠的监测系统来追踪成人百日咳感染情况和疫苗接种覆盖率。因此,我们评估了一个初级保健框架满足这一需求的可靠性。

利用一个针对15岁及以上人群的意大利初级保健数据库,我们确定了2009年至2022年期间百日咳感染报告率以及dTap疫苗/加强疫苗接种覆盖率。

在总体人群中,我们得出百日咳感染的终生发生率为每10000人中有7.52例。2009年至2022年期间,百日咳感染的年发病率在每10000人年0.008至0.001例之间。同期观察到dTap疫苗接种覆盖率呈上升趋势(从每10000人8.72剂至16.54剂)。值得注意的是,与普通人群相比,65岁及以上人群、吸烟者和/或免疫功能低下者更有可能接种dTap疫苗。

鉴于意大利公共卫生系统的组织架构,这个初级保健网络可能充当一个可靠的流行病学监测系统,以追踪成人百日咳感染情况和dTap疫苗接种覆盖率。百日咳病例报告不足,疫苗和加强疫苗的接种率较低。因此,密切监测百日咳报告和dTap疫苗接种情况并在国家层面制定干预策略以加强与疫苗相关的预防措施至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86c5/11417937/ab98280f55d5/idr-16-00068-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86c5/11417937/72bdce8af9db/idr-16-00068-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86c5/11417937/ab98280f55d5/idr-16-00068-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86c5/11417937/72bdce8af9db/idr-16-00068-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86c5/11417937/ab98280f55d5/idr-16-00068-g002.jpg

相似文献

1
Pertussis Notification Rate and Tdpa Vaccine/Booster Coverage in Adults: An Opportunity for an Epidemiological Observatory in Primary Care.成人百日咳报告率及破伤风、白喉、无细胞百日咳疫苗/加强剂接种覆盖率:基层医疗中建立流行病学监测点的契机
Infect Dis Rep. 2024 Sep 2;16(5):870-879. doi: 10.3390/idr16050068.
2
Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.婴儿期接种的三组分无细胞百日咳疫苗在生命最初6年的持续效力:意大利的经验。
Pediatrics. 2001 Nov;108(5):E81. doi: 10.1542/peds.108.5.e81.
3
Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.在婴儿期接种无细胞疫苗初免的儿童中,一剂三组分白喉-破伤风-无细胞百日咳疫苗加强免疫在学龄前儿童中的反应原性和免疫原性。
Pediatrics. 2001 Feb;107(2):E25. doi: 10.1542/peds.107.2.e25.
4
A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.12种无细胞百日咳疫苗与1种全细胞百日咳疫苗作为第四剂,在15至20月龄儿童中接种的安全性和免疫原性比较。
Pediatrics. 1997 Nov;100(5):772-88. doi: 10.1542/peds.100.5.772.
5
Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.白喉和破伤风类毒素联合全细胞百日咳疫苗或无细胞百日咳疫苗进行初次免疫,对15至21月龄儿童一剂含基因灭活百日咳毒素的无细胞百日咳疫苗加强免疫安全性和免疫原性的影响。意大利重组无细胞百日咳疫苗研究多中心小组
J Pediatr. 1995 Aug;127(2):238-43. doi: 10.1016/s0022-3476(95)70301-2.
6
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.一项 III 期、开放性标签、随机多中心研究,旨在评估在英国 3 至 4 岁健康儿童中,同时接种麻疹-腮腺炎-风疹疫苗时,两种不同低剂量抗原白喉-破伤风-无细胞百日咳-脊髓灰质炎疫苗加强剂量的免疫原性和安全性。
Vaccine. 2018 Apr 19;36(17):2300-2306. doi: 10.1016/j.vaccine.2018.03.021. Epub 2018 Mar 22.
7
Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations.b型流感嗜血杆菌破伤风结合疫苗单独接种或与白喉-破伤风类毒素及无细胞百日咳疫苗混合接种用于初次免疫和加强免疫时的免疫原性和反应原性。
Eur J Pediatr. 1998 Mar;157(3):208-14. doi: 10.1007/s004310050797.
8
Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.六种无细胞百日咳疫苗和一种全细胞百日咳疫苗在4至6岁儿童中作为第五剂接种的安全性和免疫原性。
Pediatrics. 2000 Jan;105(1):e11. doi: 10.1542/peds.105.1.e11.
9
Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy.支持意大利为学前儿童接种全剂量 DTaP-IPV 疫苗建议的科学证据综述。
Expert Rev Vaccines. 2022 Dec;21(12):1819-1830. doi: 10.1080/14760584.2022.2130770. Epub 2022 Nov 27.
10
Safety of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccine in Adults in Japan.日本成人用白喉破伤风无细胞百日咳(DTaP)疫苗的安全性。
Jpn J Infect Dis. 2021 Sep 22;74(5):399-404. doi: 10.7883/yoken.JJID.2020.947. Epub 2021 Jan 29.

本文引用的文献

1
Burden of Pertussis in Adults Aged 50 Years and Older: A Retrospective Database Study in England.50岁及以上成年人百日咳负担:英格兰的一项回顾性数据库研究
Infect Dis Ther. 2023 Apr;12(4):1103-1118. doi: 10.1007/s40121-023-00774-5. Epub 2023 Mar 16.
2
Assessment of Pertussis Underreporting in Italy.意大利百日咳漏报情况评估。
J Clin Med. 2023 Feb 21;12(5):1732. doi: 10.3390/jcm12051732.
3
Sero-Epidemiological Study of Infection in the Italian General Population.意大利普通人群感染情况的血清流行病学研究。
Vaccines (Basel). 2022 Dec 13;10(12):2130. doi: 10.3390/vaccines10122130.
4
Drivers of and barriers to routine adult vaccination: A systematic literature review.成人常规疫苗接种的驱动因素和障碍:系统文献回顾。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2127290. doi: 10.1080/21645515.2022.2127290. Epub 2022 Oct 5.
5
Experts' Opinion for Improving Pertussis Vaccination Rates in Adolescents and Adults: A Call to Action.专家意见:提高青少年和成年人百日咳疫苗接种率:行动呼吁。
Int J Environ Res Public Health. 2022 Apr 6;19(7):4412. doi: 10.3390/ijerph19074412.
6
Tdap Booster Vaccination for Adults: Real-World Adherence to Current Recommendations in Italy and Evaluation of Two Alternative Strategies.成人百白破加强疫苗接种:意大利对当前建议的真实世界依从性以及两种替代策略的评估。
Int J Environ Res Public Health. 2022 Mar 29;19(7):4066. doi: 10.3390/ijerph19074066.
7
A decade of data: Adolescent vaccination in the vaccine safety datalink, 2007 through 2016.十年数据:2007年至2016年疫苗安全数据链中的青少年疫苗接种情况
Vaccine. 2022 Feb 23;40(9):1246-1252. doi: 10.1016/j.vaccine.2022.01.051. Epub 2022 Feb 4.
8
Predicting the risk of severe COVID-19 outcomes in primary care: development and validation of a vulnerability index for equitable allocation of effective vaccines.预测初级保健中 COVID-19 重症结局的风险:为公平分配有效疫苗而制定的脆弱性指数的开发和验证。
Expert Rev Vaccines. 2022 Mar;21(3):377-384. doi: 10.1080/14760584.2022.2019582. Epub 2021 Dec 29.
9
Estimating pertussis incidence in general practice using a large Australian primary care database.利用澳大利亚大型初级保健数据库估算全科医疗中的百日咳发病率。
Vaccine. 2021 Jul 5;39(30):4153-4159. doi: 10.1016/j.vaccine.2021.05.079. Epub 2021 Jun 9.
10
Incidence and severity of pertussis hospitalisations in infants aged less than 1 year in 37 hospitals of six EU/EEA countries, results of PERTINENT sentinel pilot surveillance system, December 2015 to December 2018.2015 年 12 月至 2018 年 12 月,6 个欧盟/欧洲经济区国家的 37 家医院中,年龄不足 1 岁的婴儿百日咳住院的发生率和严重程度,PERTINENT 哨点监测系统的结果。
Euro Surveill. 2021 Jan;26(4). doi: 10.2807/1560-7917.ES.2021.26.4.1900762.